orientation and spatial frequency tuning, at each recording site for each animal. The temporal impulse functions were derived by generating a histogram of the neural responses to briefly presented flashes at random positions within the receptive field. Identical results were obtained with filters defined by parameters that were based on data obtained at each of the three age groups. The shapes of the correlational functions were relatively insensitive to the particular parameter values of the spatial and temporal filters.
Clustering neurotransmitter receptors at the synapse is crucial for efficient neurotransmission. Here we identify a Caenorhabditis elegans locus, lev-10, required for postsynaptic aggregation of ionotropic acetylcholine receptors (AChRs). lev-10 mutants were identified on the basis of weak resistance to the anthelminthic drug levamisole, a nematode-specific cholinergic agonist that activates AChRs present at neuromuscular junctions (NMJs) resulting in muscle hypercontraction and death at high concentrations [1] [2] [3] . In lev-10 mutants, the density of levamisole-sensitive AChRs at NMJs is markedly reduced, yet the number of functional AChRs present at the muscle cell surface remains unchanged. LEV-10 is a transmembrane protein localized to cholinergic NMJs and required in body-wall muscles for AChR clustering. We also show that the LEV-10 extracellular region, containing five predicted CUB domains and one LDLa domain, is sufficient to rescue AChR aggregation in lev-10 mutants. This suggests a mechanism for AChR clustering that relies on extracellular protein-protein interactions. Such a mechanism is likely to be evolutionarily conserved because CUB/LDL transmembrane proteins similar to LEV-10, but lacking any assigned function, are expressed in the mammalian nervous system and might be used to cluster ionotropic receptors in vertebrates.
Genetic screens for C. elegans mutants that exhibit strong resistance to levamisole have identified four genes encoding AChR subunits and two genes that are required for the biosynthesis of levamisole-sensitive AChRs [1] [2] [3] . However, no genes required for AChR clustering were cloned despite the large size of these screens. We hypothesized that impairing the function of such genes would generate subtle phenotypes for two reasons. First, unclustered levamisole-sensitive AChRs might remain functional if properly inserted into the plasma membrane, thus conferring levamisolesensitivity. Second, there is an additional class of AChRs present at C. elegans NMJs that are activated by acetylcholine and nicotine but are insensitive to levamisole 4 . These receptors, of as yet unknown composition, might compensate for a decrease in levamisolesensitive AChRs at the synapse.
We therefore performed a screen to isolate mutants that exhibited only weak resistance to levamisole. To facilitate the identification of mutated genes we used an insertional mutagenesis based on germline mobilization of the Drosophila transposon Mos1 (ref. 5). We isolated a mutant allele, kr26, that resulted from a Mos1 insertion whose interpolated genetic position was in the vicinity of the lev-10 locus. A single mutant allele of lev-10, x17, was isolated previously in a levamisole-resistance screen but was not characterized at the molecular level 1 . Using a genetic complementation test, we showed that x17 and kr26 are two alleles of the same gene, lev-10. Both lev-10 mutants displayed a slight resistance to levamisole, when assayed by dose-response (Fig. 1a) , but after 1 h of exposure to 1 mM levamisole, 100% of the lev-10 mutants became paralysed. Although, in contrast to wild-type animals, lev-10 mutants were able to survive while remaining hypercontracted at this elevated drug concentration. In addition, both lev-10 mutants displayed marginal locomotory defects on plates. When movement was analysed in liquid medium, a subtle but significant movement impairment was detected (Fig. 1b) . These phenotypes suggested that mutating lev-10 only partly impairs the function of levamisole-sensitive AChRs.
To analyse the expression of these receptors, we raised antibodies against UNC-29, a non-a-subunit of the levamisole-sensitive AChR in muscle 6 . In wild-type animals, UNC-29 was clustered along the ventral and dorsal cords and in the nerve ring where head muscles are innervated (Fig. 2a, c) . In lev-10 mutants, no detectable UNC-29 staining was observed along the ventral and dorsal nerve cords, and only weak staining remained in the nerve ring (Fig. 2b, d ). To test whether the loss of UNC-29 clusters in lev-10 mutants was due to the absence of cholinergic innervation, we immunostained cholinergic varicosities with an antibody against UNC-17, the vesicular acetylcholine transporter in C. elegans 7 . Staining patterns were similar in wild-type (Fig. 2e) and lev-10 mutant animals ( Fig. 2f) . In addition to cholinergic innervation, body-wall muscles are also innervated by GABAergic motoneurons. To determine whether lev-10 was globally required for the formation of receptor aggregates or was specifically acting at cholinergic neuromuscular synapses, we immunostained the muscle GABA A receptor UNC-49 (refs 8, 9) . In both the wild type and lev-10 mutants, GABA receptors were clustered along the nerve cords (Fig. 2g, h ). The inability to detect AChRs by immunostaining could result from decreased receptor expression in lev-10 mutants. Alternatively, a diffuse distribution of a wild-type number of receptors could be below our detection threshold. AChR expression was therefore assessed by western blot analysis of fractionated worm extracts (Fig. 2i) . In lev-10(kr26) and lev-10(x17) extracts, the UNC-29 concentrations were similar to that in the wild type (90^12% (n ¼ 4) and 123^17% (n ¼ 4), respectively), suggesting that AChR expression is not reduced in lev-10 mutants.
To test whether the UNC-29 protein detected in lev-10 mutants was assembled into functional receptors present at the muscle cell surface, we used electrophysiology 4 . Pressure-ejection of levamisole onto voltage-clamped body-wall muscles elicited similar currents in the wild type and in lev-10 mutants (Fig. 3a, b ), whereas in a unc-29 lev-10 double mutant no levamisole current was detected (data not shown). These data indicate that the overall expression level of functional levamisole-sensitive AChRs in lev-10 mutants is comparable to that in the wild type. To analyse the synaptic population of levamisole-sensitive AChRs, we stimulated motoneurons in the ventral cord and recorded evoked currents in individual muscle cells. To eliminate currents due to activation of the GABA receptor UNC-49, we performed our analysis in an unc-49(e407) null mutant background. Furthermore, we used the nicotinic antagonist dihydro-b-erythroidine (DHbE) to block levamisole-insensitive AChRs present at NMJs 4 . In lev-10;unc-49 double mutants, the size of the evoked response in the presence of DHbE was decreased by 77% compared with that of unc-49 (Fig. 3c, d ). The remaining evoked current was due to the activation of levamisole-sensitive AChRs, because unc-29;unc-49 double mutants, which no longer express levamisole-sensitive AChRs 4 , exhibited no evoked response in the presence of DHbE. In addition, the time to peak and decay time of the evoked current were increased in lev-10;unc-49 compared with those in unc-49 (6.44^0.41 ms (n ¼ 7) versus 4.64^0.18 ms (n ¼ 7), p , 0.0017, and 16.6^6.9 ms (n ¼ 6) versus 8.4^0.43 ms (n ¼ 7), p , 0.0002, respectively). These kinetic alterations are consistent with a decreased ratio of synaptic versus perisynaptic receptors being activated by synaptic release of acetylcholine in the lev-10 background. Analysis of evoked response amplitudes in the absence of DHbE in lev-10;unc-49 and unc-49 mutants did not reveal any significant difference (3329^221 pA (n ¼ 6) versus 2904^291 pA (n ¼ 7), respectively), thus suggesting that the expression and localization of the levamisoleinsensitive AChRs present at the NMJ were not affected in lev-10 mutants. In combination with the immunostaining data, these results indicate that lev-10 is required specifically for the clustering of levamisole-sensitive AChRs at the synapse.
We cloned lev-10 using inverse polymerase chain reaction (PCR) to identify the genomic position of the kr26::Mos1 insertion (Fig. 4a) and confirmed its identity by rescue experiments (Supplementary  Table S1 ). Interestingly, lev-10 overlaps with eat-18, a gene required for the function of AChRs in pharyngeal muscle 10, 11 . Mutation of eat-18 does not confer levamisole resistance. We confirmed that these genes are distinct by genetic complementation (data not shown) and by rescuing lev-10 mutants with a genomic fragment carrying the eat-18(ad1110) nonsense mutation (Supplementary Table S1 ). lev-10 is predicted to encode a type I transmembrane protein (Fig. 4b) . The extracellular part of the protein contains five predicted CUB domains and one LDLa domain. These domains are present in a wide variety of secreted and membrane-bound proteins and mediate protein-protein interactions (for reviews see refs [12] [13] [14] . Alternative splicing of lev-10 generates two transcripts, lev-10a and lev-10b (Fig. 4b) . The lev-10b splice variant represents less than 10% of lev-10 mRNAs (data not shown) and codes for a LEV-10 isoform that differs from LEV-10A in the transmembrane region and contains virtually no intracellular region.
In wild-type animals, LEV-10 is concentrated at cholinergic NMJs (Fig. 5a, c, e) . Double labelling experiments with an antibody against the vesicular acetylcholine transporter UNC-17 (ref. 15) demonstrated that 93^3% of LEV-10 puncta were associated with cholinergic varicosities (mean^SEM, 104 puncta counted in seven worms). However, three-dimensional analysis of confocal image stacks revealed that LEV-10 staining was juxtaposed to, but did not overlap, UNC-17 distribution (Fig. 5f ). To determine whether LEV-10 functions postsynaptically, we expressed LEV-10A or LEV-10B under the control of the muscle-specific promoter myo-3 (ref. 16 ) in lev-10(kr26) animals. Both proteins rescued behavioural defects and UNC-29 synaptic clustering when expressed in muscle (Supplementary Table S1 ). Genetic mosaic -18 (hatched boxes) . The eat-18 exon is spliced to the second exon of lev-10 by using a different frame, which ends 16 bp after the splice site. ad1110, nonsense mutation in the first exon of eat-18. b, Predicted structure of the LEV-10 isoforms. Horizontal black line, signal peptide; CUB, complement, urchin epidermal growth factor, and bone morphogenetic protein domain; LDLa, low-density lipoprotein receptor domain class A; TM, transmembrane region; aa, amino acids. Domain predictions were based on SMART (http://smart.embl-heidelberg.de).
analysis (Supplementary Information) confirmed that LEV-10 is required cell autonomously in postsynaptic muscle cells for AChR clustering at NMJs.
Recent results have suggested that proteins involved in neurotransmitter receptor clustering do not accumulate at the synapse in the absence of the receptors 17 . To test this possibility in our system, we analysed the distribution of LEV-10 in animals lacking levamisole-sensitive AChRs. In unc-29(x29) and unc-38(x20) AChR subunit mutants, no LEV-10 was detected in ventral and dorsal nerve cords by immunofluorescence (Fig. 5b and data not shown) even though presynaptic cholinergic varicosities differentiated normally (Fig. 5d) . In parallel, LEV-10 expression level was assessed by western blot analysis (Fig. 5g) . LEV-10 was detected as a 120-kDa protein present in the membrane fraction of wild-type worm extracts. This band was absent from lev-10(kr26) extracts and was markedly reduced in lev-10(x17). In unc-29 and unc-38 extracts, LEV-10 concentrations were decreased only slightly in comparison with those in the wild type (72%^11 (n ¼ 4) and 81%^4 (n ¼ 5), respectively), indicating that a lack of levamisole-sensitive AChRs does not alter LEV-10 expression level. Because LEV-10 is expressed but fails to accumulate at synapses in the absence of levamisole-sensitive AChRs, we cannot exclude the possibility that LEV-10 requires AChRs to reach the plasma membrane, although no intracellular staining of LEV-10 is seen by immunofluorescence in unc-29 and unc-38 mutants. Alternatively, LEV-10 might interact directly or indirectly with AChRs in a complex that is recruited or stabilized at the synapse.
Because most characterized ionotropic receptor clustering proteins are cytoplasmic, relevant interactions are thought to occur on the cytoplasmic side of the postsynaptic membrane 18, 19 . However, complexes formed on the extracellular side of the postsynaptic membrane might also be critical [20] [21] [22] [23] . To test this possibility, we fused the extracellular part of LEV-10 to the human CD4 transmembrane domain. Expression of this chimaeric protein in muscle rescued the defects in levamisole sensitivity, locomotion and AChR clustering of lev-10(kr26) animals. Furthermore, we overexpressed a green fluorescent protein (GFP)-tagged version of LEV-10 truncated before the transmembrane segment. This protein was secreted from muscle cells into the pseudocoelomic cavity (data not shown) but was still able to rescue lev-10(kr26) mutant phenotypes (Supplementary Table S1 ). The function of LEV-10 in AChR clustering therefore seems to involve only extracellular interactions.
LEV-10 is the first example of a CUB/LDL protein involved in the synaptic clustering of AChRs. The presence of multiple predicted protein-protein interaction domains in the extracellular region indicates that LEV-10 might bind multiple partners. Because we have so far been unable to demonstrate direct interactions between LEV-10 and AChRs, LEV-10 might be indirectly involved in the recruitment of signalling molecules that, in turn, cause AChR clustering. However, the interdependence between LEV-10 and AChR for synaptic localization is consistent with a model that would involve a set of interactions between LEV-10, AChRs or AChR-associated proteins, and a synaptic determinant used to nucleate clustering. Along this line, another C. elegans CUBdomain-rich transmembrane protein, SOL-1, has recently been shown to physically interact with glutamate receptors and to be required for glutamate-gated currents through an as yet unidentified mechanism 24 . Of 145 CUB-domain-containing mouse proteins present in nonredundant databases, the first two CUB domains of LEV-10 are most similar to those present in NETO2 (ref. 25) (26% identity, 43% similarity). NETO2 and its paralogue NETO1/BTCL1 (refs 25, 26) are predicted type I transmembrane proteins containing two CUB domains and one LDLa domain in their extracellular region. The two NETO genes are specifically expressed in retina and brain, but their function is unknown. It is therefore tempting to speculate that LEV-10 and NETO proteins are members of a novel class of membrane-spanning proteins engaged in postsynaptic domain organization by means of extracytoplasmic interactions at the synapse.
A
Methods
Cloning of lev-10 Rescue experiments were performed with a genomic fragment covering the Y105E8A.7a coding region plus 5 kilobases (kb) upstream of the translational start site and 0.21 kb downstream of the lev-10a stop codon. This 15-kb fragment was amplified from N2 or eat-18(ad1110) 11 genomic DNA and was injected at 0.85 ng ml 21 with the use of pTG96 (sur-5::GFP) 27 as a co-injection marker at 100 ng ml
21
. Rescue was scored on the basis of survival on 1 mM levamisole for 16 h.
Tissue-specific rescue lev-10 complementary DNAs were cloned by PCR after reverse transcription, and sequenced. SL1 splicing was established by PCR with an SL1 primer and a primer in lev-10 exon 13, and by sequencing the expressed sequence tag yk796a04.3 0 . PCR with rapid amplification of cDNA ends (RACE-PCR) was used to localize the polyadenylation site. lev-10a and lev-10b cDNAs were subcloned into pPD115.62 under the control of the myo-3 promoter. The CD4 transmembrane domain amplified from the human CD4 cDNA (GenBank accession number M12807) was subcloned in frame into Pmyo-3::lev-10a and a stop codon was introduced immediately after the CD4 transmembrane domain. The secreted gfp-lev-10 s was obtained by removing the CD4 transmembrane domain from Pmyo-3::lev-10-CD4 and inserting a GFP cDNA immediately after the lev-10 signal peptide. All constructs were injected at 20 ng ml 21 together with pTG96 (80 ng ml
) except for Pmyo-3::gfp-lev-10 s (10 ng ml
).
Levamisole dose-response curve
Young adult worms were scored blind for paralysis after 1 h exposure to levamisole. A distance of one body length of forward movement after mechanical stimulus was required to score a worm as non-paralysed.
Electrophysiological studies
Electrophysiological methods were performed as described previously 4 . Muscle recordings were made in the whole-cell voltage-clamp configuration (holding potential 260 mV) with an EPC-10 patch-clamp amplifier and digitized at 1 kHz. Data were acquired by Pulse software (HEKA). The bath solution contained 150 mM NaCl, 5 mM KCl, 5 mM CaCl 2 , 1 mM MgCl 2 , 10 mM glucose and 15 mM HEPES, pH 7.35, about 340 mOsm. The pipette solution was prepared as described previously 4 . Subsequent analysis and graphing were performed with Pulsefit (HEKA) and Igor Pro. All statistically derived values are given as means^s.e.m.
Antibody production and immunocytochemistry
UNC-29: a DNA fragment encoding UNC-29 amino acids 348-431 was inserted into pGEX-3X (Amersham Biosciences). The glutathione-S-transferase (GST)-UNC-29 Figure 5 LEV-10 is a synaptic protein that requires levamisole-sensitive AChRs for proper localization but not for expression. a, LEV-10A immunostaining in the dorsal cord of a wild-type animal. c, UNC-17 immunostaining of the same animal labels cholinergic varicosities. e, Merged images. f, Z-optical projection through the entire stack of confocal images at the level of the dashed arrow in e. b, d, LEV-10A (b) and UNC-17 (d) immunostaining in the dorsal cord of an unc-29(x29) mutant. Scale bar, 10 mm. g, Western blot analysis of fractionated C. elegans extracts. P, pellet; S, cytosolic supernatant. The LEV-10 transmembrane protein has an apparent molecular mass of about 120 kDa. Mutants of the levamisole-sensitive AChR subunits unc-29(x29) and unc-38(x20) have LEV-10 concentrations at the membrane comparable to those of the wild type.
fusion protein was expressed in Escherichia coli and purified in accordance with the manufacturer's protocol. Rabbits were injected with 100 mg of fusion protein and boosted three times with 100 mg each.
LEV-10: two synthetic peptides (Eurogentec) corresponding to the LEV-10A amino acids 847-861 and 892-906 were injected into rabbits as described for UNC-29. Both antibodies were purified as described previously 28 by using the fusion proteins GST-UNC-29 or GST-LEV-10A (amino acids 836-906 in pGEX-3X) blotted on nitrocellulose. Immunostaining was performed as described 9 . UNC-29 antibody was used at a dilution of 1:250, and LEV-10 antibody at 1:300. For double-labelling experiments, UNC-17 monoclonal antibody 15 was diluted at 1:500 and incubated for 1 h; after 1 h of washing, UNC-29 or LEV-10 antibodies were incubated overnight. The secondary antibody, Cy3-labelled goat anti-rabbit IgG (H þ L) (Jackson ImmunoResearch Laboratories), was diluted at 1:900 and the secondary antibody, Alexa488-labelled goat anti-mouse (Molecular Probes) at 1:200.
Protein extraction and western blotting
A mixed staged population of worms (500 ml) was frozen at 280 8C until use. For extraction, worm pellets were ground under liquid nitrogen and thawed on ice. While thawing, 6-10 volumes of ice-cold homogenization buffer (20 mM HEPES pH 7.4, 10 mM KCl, 1 mM EDTA, 400 mM Pefabloc (Roche) and Complete Mini Protease inhibitor cocktail (Roche)) were added and the suspension was further homogenized with ten strokes with the use of a 2-ml tight-fitting glass tissue homogenizer. Afterwards an equal volume of homogenization buffer containing 0.5 M sucrose was added and the suspension was centrifuged twice at 2,000g for 10 min to remove worm debris. The resulting nuclear pellets were pooled and extracted twice with 5 ml of homogenization buffer containing 0.25 M sucrose. The post-nuclear supernatants were pooled and subsequently centrifuged at 150,000g for 1 h. Equal amounts (about 30 mg) of the resulting cytosolic supernatant and membrane pellet were separated by SDS-polyacrylamide-gel electrophoresis and blotted onto nitrocellulose membranes. The membranes were subsequently probed with purified anti-LEV-10 serum (dilution 1:1000), anti-UNC-29 (1:600) or anti-VHA-5 (1:3000) (M. Labouesse, unpublished observations) and horseradish-peroxidase-conjugated goat anti-rabbit antibodies (DAKO) and revealed with LumiLight reagents (Roche).
